Preclinical Activity of Multiple-Target Gold(III)-Dithiocarbamato Peptidomimetics in Prostate Cancer Cells and Xenografts

References

• Jemal A , SiegelR, XuJet al. Cancer statistics 2010. CA Cancer J. Clin.60 (5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Stavridi F , KarapanagiotouEM, SyrigosKN. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat. Rev.36 (2), 122–130 (2010).
   PubMed Web of Science ®Google Scholar
• Barry NPE , SadlerPJ. Exploration of the medical periodic table: towards new targets. Chem. Commun.49, 5106–5131 (2013).
   PubMed Web of Science ®Google Scholar
• Nagy EM , RonconiL, NardonCet al. Noble-metal dithiocarbamates: precious allies in the fight against cancer. Mini-Rev. Med. Chem.12 (12), 1216–1229 (2012).
   PubMed Web of Science ®Google Scholar
• Pabla N , DongZ. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int.73 (9), 994–1007 (2008).
   PubMed Web of Science ®Google Scholar
• Marzano C , RonconiL, ChiaraFet al. Gold(III)-dithiocarbamato anticancer agents: activity, toxicology and histopathological studies in rodents. Int. J. Cancer129 (2), 487–496 (2011).
   PubMed Web of Science ®Google Scholar
• Ronconi L , GiovagniniL, MarzanoCet al. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity. Inorg. Chem.44 (6), 1867–1881 (2005).
   PubMed Web of Science ®Google Scholar
• Aldinucci D , LorenzonD, StefaniLet al. Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro. Anticancer Drugs18 (3), 323–332 (2007).
   PubMed Web of Science ®Google Scholar
• Milacic V , ChenD, RonconiLet al. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res.66 (21), 10478–10486 (2006).
   PubMed Web of Science ®Google Scholar
• Cattaruzza L , FregonaD, MongiatMet al. Antitumour activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts. Int. J. Cancer.128 (1), 206–215 (2011).
   PubMed Web of Science ®Google Scholar
• Chiara F , GambalungaA, SciacovelliMet al. Chemotherapeutic induction of mitochondrial oxidative stress activates GSK-3α/β and Bax, leading to permeability transition pore opening and tumor cell death. Cell Death Dis.3, e444 (2012).
   PubMed Web of Science ®Google Scholar
• Ronconi L , AldinucciD, DouQPet al. Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes. Anti-Cancer Agents Med. Chem.10 (4), 283–292 (2010).
   PubMed Web of Science ®Google Scholar
• Dalla Via L , Nardon, C, FregonaD. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Future Med. Chem.4 (4), 525–543 (2012).
   PubMed Web of Science ®Google Scholar
• Saggioro D , RigobelloMP, PaloschiLet al. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem. Biol.14 (10), 1128–1139 (2007).
   PubMedGoogle Scholar
• Casini A , MessoriL. Molecular mechanisms and proposed targets for selected anticancer gold compounds. Curr. Top. Med. Chem.11 (21), 2647–2660 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang X , FrezzaM, MilacicVet al. Inhibition of tumour proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes. J. Cell. Biochem.109 (1), 162–172 (2010).
   PubMed Web of Science ®Google Scholar
• Rubio-Aliaga I , DanielH. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica38 (7–8), 1022–1042 (2008).
   PubMed Web of Science ®Google Scholar
• Mitsuoka K , MiyoshiS, KatoYet al. Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter. J. Nucl. Med.49 (4),  615–622  (2008).
   PubMed Web of Science ®Google Scholar
• Tai W , ChenZ, ChengK. Expression profile and functional activity of peptide transporters in prostate cancer cells. Mol. Pharm.10 (2), 477–487 (2012).
   PubMedGoogle Scholar
• Brandsch M , KnütterI, Bosse-DoneckeE. Pharmaceutical and pharmacological importance of peptide transporters. J. Pharm. Pharmacol.60 (5), 543–585 (2008).
   PubMed Web of Science ®Google Scholar
• Brandsch M . Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opin. Drug Metab. Toxicol.5 (8), 887–905 (2009).
   PubMed Web of Science ®Google Scholar
• Negom Kouodom M , RonconiL, CelegatoMet al. Toward the selective delivery of chemotherapeutics into tumor cells by targeting petide transporters: tailored gold-based anticancer peptidomimetics. J. Med. Chem.55 (5), 2212–2226 (2012).
   PubMed Web of Science ®Google Scholar
• Negom Koudom M , BoscuttiG, CelegatoMet al. Rational design of gold(III)-dithiocarbamato peptidomimetics for the targeted anticancer chemotherapy. J. Inorg. Biochem.117, 248–260 (2012).
   PubMed Web of Science ®Google Scholar
• Lincoln DT , Ali EmadiEM, TonissenKFet al. The thioredoxin–thioredoxin reductase system: over-expression in human cancer. Anticancer Res.23 (3B), 2425–2433 (2003).
   PubMed Web of Science ®Google Scholar
• Tonissen KF , DiTG. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol. Nutr. Food Res.53 (1), 87–103 (2009).
   PubMed Web of Science ®Google Scholar
• Cadenas C , FranckensteinD, SchmidtMet al. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res.12 (3), R44 (2010).
   PubMed Web of Science ®Google Scholar
• Sun Y , RigasB. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res.68 (20), 8269–8277 (2008).
   PubMed Web of Science ®Google Scholar
• Singh SS , LiY, FordOHet al. Thioredoxin reductase 1 expression and castration-recurrent growth of prostate cancer. Transl. Oncol.1 (3), 153–157 (2008).
   PubMed Web of Science ®Google Scholar
• Shan W , ZhongW, ZhaoRet al. Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression. Free Radic. Biol. Med.49 (12), 2078–2087 (2010).
   PubMed Web of Science ®Google Scholar
• Yamada M , TomidaA, YoshikawaHet al. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin. Cancer Res.2 (2), 427–432 (1996).
   PubMed Web of Science ®Google Scholar
• Kim SJ , MiyoshiY, TaguchiTet al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res.11 (23), 8425–8430 (2005).
   PubMed Web of Science ®Google Scholar
• Eriksson SE , Prast-NielsenS, FlabergEet al. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic. Biol. Med.47 (11), 1661–1671 (2009).
   PubMed Web of Science ®Google Scholar
• Powis G , KirkpatrickDL. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol.7 (4), 392–397 (2007).
   PubMed Web of Science ®Google Scholar
• Rackham O , NicholsSJ, LeedmanPJet al. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria. Biochem. Pharmacol.74 (7), 992–1002 (2007).
   PubMed Web of Science ®Google Scholar
• Shen M , SchmittS, BuacDet al. Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin. Ther. Targets17 (9), 1091–108 (2013).
   PubMed Web of Science ®Google Scholar
• Wu WK , ChoCH, LeeCWet al. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett.293 (1), 15–22 (2010).
   PubMed Web of Science ®Google Scholar
• Kisselev AF , vander Linden WA, OverkleeftHS. Proteasome inhibitors: an expanding army attacking a unique target. Chem. Biol.19 (1), 99–115 (2012).
   PubMed Web of Science ®Google Scholar
• Bonaccorsi L , MarchianiS, MuratoriMet al. Gefitinib (‘IRESSA’, ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J. Cancer Res. Clin. Oncol.130 (10), 604–614 (2004).
   PubMed Web of Science ®Google Scholar
• Gan Y , ShiC, IngeLet al. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene29 (35), 4947–4958 (2010).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G , TortoraG, D'ArmientoFPet al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res.8 (11), 3438–3444 (2002).
   PubMed Web of Science ®Google Scholar
• Schlomm T , KirsteinP, IwersLet al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin. Cancer Res.13 (22), 6579–6584 (2007).
   PubMed Web of Science ®Google Scholar
• Bratland A , BoenderPJ, HoifodtHKet al. Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling. Clin. Exp. Metastasis26 (5), 485–496 (2009).
   PubMed Web of Science ®Google Scholar
• Bonaccorsi L , MarchianiS, MuratoriMet al. Signaling mechanisms that mediate invasion in prostate cancer cells. Ann. NY Acad. Sci.1028, 283–288 (2004).
   PubMed Web of Science ®Google Scholar
• Liang CC , ParkAY, GuanJL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc.2 (2), 329–333 (2007).
   PubMed Web of Science ®Google Scholar
• Chou TC , TalalayP. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul.22, 27–55 (1984).
   PubMedGoogle Scholar
• Nefedova Y , LandowskiTH, DaltonWS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia17 (6), 1175–1182 (2003).
   PubMed Web of Science ®Google Scholar
• Campos CB , PaimBA, CossoRGet al. Method for monitoring of mitochondrial cytochrome c release during cell death: Immunodetection of cytochrome c by flow cytometry after selective permeabilization of the plasma membrane. Cytometry A69 (6), 515–523 (2006).
   PubMedGoogle Scholar
• UTHSCSA ImageToolVersion 3.0. http://compdent.uthscsa.edu/dig/itdesc.html
   Google Scholar
• Zhang F , TangJM, WangLet al. Phosphorylation of epidermal growth factor receptor and chromosome 7 polysomy in gastric adenocarcinoma. J. Dig. Dis.13 (7), 350–359 (2012).
   PubMed Web of Science ®Google Scholar
• Center MM , JemalA, Lortet-TieulentJet al. International variation in prostate cancer incidence and mortality rates. Eur. Urol.61 (6), 1079–1092 (2012).
   PubMed Web of Science ®Google Scholar
• Kang MH , ReynoldsCP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res.15 (4), 1126–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Brunelle JK , LetaiA. Control of mitochondrial apoptosis by the Bcl-2 family. J. Cell. Sci.122 (4), 437–441 (2009).
   PubMed Web of Science ®Google Scholar
• Zhuang S , OuedraogoGD, KochevarIE. Downregulation of epidermal growth factor receptor signaling by singlet oxygen through activation of caspase-3 and protein phosphatases. Oncogene22 (28), 4413–4424 (2003).
   PubMed Web of Science ®Google Scholar
• Fregona D , RonconiL, FormaggioFet al. WO2010105691A1 (2010).
   Google Scholar